What is Desentum?
Founded in 2011 as a spin-off from the VTT Technical Research Centre of Finland, Desentum specializes in the development of next-generation immunotherapeutic solutions. The company's core technology focuses on re-engineering the immune system's response to allergens, effectively shifting the body from a state of hypersensitivity to one of tolerance. This mechanism represents a significant departure from traditional symptom-management therapies, positioning Desentum as a high-potential player in the global allergy treatment market. With a history of recognition, including the prestigious EARTO Innovation Prize, the company maintains a rigorous focus on clinical validation and scientific excellence.
How much funding has Desentum raised?
Desentum has raised a total of $15.5M across 3 funding rounds:
Series A
$2M
Other Financing Round
$4.5M
Unspecified
$9M
Series A (2017): $2M, investors not publicly disclosed
Other Financing Round (2019): $4.5M, investors not publicly disclosed
Unspecified (2022): $9M supported by Springvest Oyj
Key Investors in Desentum
Springvest Oyj
A Finnish investment firm specializing in growth capital and equity financing for innovative companies seeking to scale their operations.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Desentum?
With the recent capital injection, Desentum is well-positioned to advance its clinical trial programs and expand its operational footprint. The strategic focus will likely center on scaling the manufacturing of its hypoallergen candidates and navigating the regulatory pathways required for market entry. As the company moves deeper into its enterprise-level growth phase, the emphasis will shift toward commercialization readiness and potential partnerships with larger pharmaceutical entities. This trajectory suggests a sustained commitment to addressing the unmet needs of patients suffering from severe allergic conditions, supported by a robust intellectual property portfolio and a clear roadmap for therapeutic delivery.
See full Desentum company page
